Your browser doesn't support javascript.
loading
Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.
Advani, Shailesh Mahesh; Advani, Pragati Shailesh; Brown, Derek W; DeSantis, Stacia M; Korphaisarn, Krittiya; VonVille, Helena M; Bressler, Jan; Lopez, David S; Davis, Jennifer S; Daniel, Carrie R; Sarshekeh, Amir Mehrvarz; Braithwaite, Dejana; Swartz, Michael D; Kopetz, Scott.
Afiliación
  • Advani SM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0426, Houston, TX, 77030, USA. Shailesh.advani@nih.gov.
  • Advani PS; Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, 20007, USA. Shailesh.advani@nih.gov.
  • Brown DW; Social Behavioral Research Branch, National Human Genome Research Institute, National Institute of Health, Bethesda, MD, 20892, USA. Shailesh.advani@nih.gov.
  • DeSantis SM; Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Institutes of Health, National Cancer Institute, Rockville, MD, 20850, USA.
  • Korphaisarn K; Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
  • VonVille HM; Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
  • Bressler J; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0426, Houston, TX, 77030, USA.
  • Lopez DS; Library, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
  • Davis JS; Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
  • Daniel CR; Division of Urology- UTHealth McGovern Medical School, Houston, TX, 77030, USA.
  • Sarshekeh AM; Department of Preventive Medicine and Community Health, UTMB Health-School of Medicine, Galveston, TX, 77555-1153, USA.
  • Braithwaite D; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Swartz MD; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0426, Houston, TX, 77030, USA.
BMC Cancer ; 19(1): 964, 2019 Oct 17.
Article en En | MEDLINE | ID: mdl-31623592
BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis. METHODS: We searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques. RESULTS: The pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21-24%; I2 = 94.75%). Pooled prevalence of CIMP-H across Asia, Australia, Europe, North America and South America was 22, 21, 21, 27 and 25%, respectively. Meta-regression analysis identified no significant differences in the prevalence of CIMP-H across geographical regions after correction for methodological variations. In exploratory analysis, we observed variations in CIMP-H prevalence across countries. CONCLUSION: Although no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenotipo / Neoplasias Colorrectales / Islas de CpG / Metilación de ADN Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans País/Región como asunto: Asia / Europa Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenotipo / Neoplasias Colorrectales / Islas de CpG / Metilación de ADN Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans País/Región como asunto: Asia / Europa Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos